According to filings with the U.S. Securities and Exchange Commission, Monarch Medical Technologies is raising $5,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Christophe Mallard played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Monarch Medical Technologies
Monarch Medical Technologies is a digital health company committed to helping hospitals and health systems deliver optimal glycemic management for critical care and non-critical care patients alike. Insulin dosing has always been a daunting and time-intensive task, but now that burnout and staffing constraints have reached record highs, never have the associated risks and challenges been more acute. Add the impacts of new CMS measures for hyperglycemia and hypoglycemia, and you have the perfect storm. Our FDA-cleared EndoTool Glucose Management System is designed specifically to displace traditional manual methods of insulin dosing with an intuitive and easy-to-use software application that integrates seamlessly with your EMR. This pioneering clinical decision support platform offers both intravenous and subcutaneous modalities, and has been shown to safely and reliably achieve and maintain target glucose goals. Specialized features help clinicians address the complexities of treating patients with diabetic ketoacidosis (DKA), hyperosmolar hyperglycemic nonketotic syndrome (HHS), gestational diabetes, impaired kidney function, residual insulin, and presence of steroids.

To learn more about Monarch Medical Technologies, visit http://www.monarchmedtech.com/

Contact:
Christophe Mallard, Chief Executive Officer
855-363-7475

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved